Cue Biopharma (CUE) Income from Non-Controlling Interests (2018 - 2025)

Cue Biopharma has reported Income from Non-Controlling Interests for 7 years, with the latest figure at $1000.0 in Q3 2025.

• Quarterly Income from Non-Controlling Interests changed N/A year-over-year to $1000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $1000.0 (changed N/A YoY) and the FY2023 annual result came in at $96000.0, up 200.0% from the prior year.
• Income from Non-Controlling Interests slipped to $1000.0 in Q3 2025 per CUE's latest filing, from $5000.0 in the prior quarter.
• Over five years, Income from Non-Controlling Interests peaked at $57000.0 in Q1 2023 and troughed at -$92000.0 in Q3 2022.
• A 4-year average of -$766.38 and a median of $434.5 in 2021 frame the typical range for Income from Non-Controlling Interests.
• The sharpest annual moves came in 2022 and 2023: Income from Non-Controlling Interests slumped 2953.44% in 2022, then jumped 105.43% in 2023.
• Over 4 years, Income from Non-Controlling Interests stood at -$131.0 in 2021, then plunged by 2953.44% to -$4000.0 in 2022, then jumped by 225.0% to $5000.0 in 2023, then tumbled by 80.0% to $1000.0 in 2025.
• According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered $1000.0, $5000.0, and $34000.0 for Q3 2025, Q3 2023, and Q2 2023 respectively.